Insulet Corporation (10-Q) Summary
Business Context and Reporting Period
Company: Insulet Corporation
Reporting Period: Quarter and six months ended June 30, 2009
Business Overview: Insulet develops, manufactures, and markets the OmniPod Insulin Management System for insulin-dependent diabetes. The system consists of a disposable insulin infusion device and a handheld Personal Diabetes Manager (PDM). The company transitioned manufacturing of completed OmniPods to a contract manufacturer (Flextronics) in China during 2008 to reduce costs and increase capacity.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Jun 30, 2009 |
3 Months Ended Jun 30, 2008 |
6 Months Ended Jun 30, 2009 |
6 Months Ended Jun 30, 2008 |
|---|---|---|---|---|
| Revenue | $14,617 | $7,417 | $27,086 | $14,088 |
| Gross Profit (Loss) | $3,169 | $(2,368) | $5,164 | $(5,695) |
| Gross Margin % | 21.7% | (31.9%) | 19.1% | (40.4%) |
| Operating Loss | $(16,445) | $(22,139) | $(33,917) | $(42,152) |
| Net Loss | $(20,239) | $(24,034) | $(39,884) | $(43,908) |
| Net Loss Per Share | $(0.73) | $(0.87) | $(1.43) | $(1.60) |
| Cash and Equivalents | $52,362 (as of Jun 30, 2009) | |||
| Long-Term Debt | $60,172 (as of Jun 30, 2009) | |||
| Accumulated Deficit | $(290,234) (as of Jun 30, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 97% for the quarter and 92% for the six months compared to the prior year periods. This was driven by an increased number of patients, higher reorder rates, and additional revenue from an agreement with Abbott Diabetes Care ($1.0M and $2.1M recognized in the 3 and 6 months of 2009, respectively).
- Gross Margin Improvement: The company moved from a gross loss to a gross profit. This improvement is attributed to increased manufacturing capacity, lower per-unit raw material costs, and the transition to Flextronics manufacturing, which improved overhead absorption.
- Interest Expense: Net interest expense increased significantly (100% for the quarter, 240% for six months) due to the full-year impact of the 5.375% Convertible Senior Notes issued in June 2008 and the adoption of FSP APB 14-1, which required reclassifying a portion of debt to equity and recognizing additional non-cash interest expense.
- Operating Expenses: Total operating expenses remained relatively flat year-over-year, with slight increases in General and Administrative expenses offset by decreases in Sales and Marketing expenses (due to reduced sample kit costs).
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses in the near term to achieve profitable growth. Focus areas for the remainder of 2009 include reducing per-unit production costs, expanding sales in domestic and international markets, and reducing operating expenses.
- Liquidity: As of June 30, 2009, the company held $52.4 million in cash. It entered into a Facility Agreement in March 2009 allowing for up to $60 million in loans (initial draw of $27.5 million made). Management believes current cash and borrowing capacity are sufficient for at least the next 12 months.
- Key Risks:
- Dependence on third-party payors for reimbursement; adverse changes in reimbursement rates could hinder market penetration.
- Reliance on a single product (OmniPod System).
- Dependence on third-party suppliers (Flextronics) for manufacturing.
- Historical operating losses and accumulated deficit of $290.2 million.
- Significant debt obligations, including $85 million in convertible notes and the Facility Agreement.
Investor Verification Checklist
- Reimbursement Status: Verify the stability of third-party insurance reimbursement rates and coverage for the OmniPod System, as this is critical for revenue growth.
- Debt Covenants: Review the specific financial performance milestones required to draw down the remaining $32.5 million on the Facility Agreement.
- Manufacturing Costs: Monitor whether the projected per-unit cost reductions from the Flextronics partnership are being realized as sales volumes increase.
- Convertible Notes: Assess the dilution risk associated with the $85 million in 5.375% Convertible Senior Notes (conversion price approx. $21.35) and the impact of FSP APB 14-1 on future interest expenses.
- Cash Burn: Track the rate of cash consumption against the $52.4 million cash balance to ensure runway extends beyond the 12-month management projection.